UK: Reverse Payments In Patent Settlements – "Pay For Delay"?

Last Updated: 8 April 2014
Article by Jennifer Pierce and Christopher Birch

It is a well established principle of competition law that a payment by one competitor to another competitor in return for the second competitor staying out of the market is anti-competitive. Whether that principle applies in the context of settlement of patent disputes is an issue which has recently been examined on both sides of the Atlantic.

Both the US Supreme Court, in the case of FTC v Actavis, Inc and the European Commission (the "Commission"), in its investigation into the dealings of the pharmaceutical company Lundbeck, have now ruled that settlements of patent litigation proceedings which involve the patent owner paying consideration to the alleged infringer and result in delay to the entry to the market of competing generic drugs may lead to serious infringement of competition laws.

European Commission Proceedings

The Commission has been monitoring patent settlement agreements in the pharmaceutical sector since 2009 in order to indentify those settlements which violate competition law. The Commission's report in 2012 indicates that 11 per cent of the settlement agreements it reviewed in 2011 are likely to be problematic from a competition law perspective.


This investigation involved Lundbeck's citalopram product, a very successful antidepressant drug.

After Lundbeck's basic patent for the citalopram molecule expired, it was faced with relying on a number of related process patents which provided more limited protection. Producers of cheaper, generic versions of citalopram therefore sought to enter the market. Generic competition generally drives prices down significantly, reducing the profits of the originator of the product and directly benefitting patients.

However, according to the Commission's finding, in 2002 Lundbeck entered into agreements with several producers of generic medicines (namely Alpharma, Merck, Arrow and Ranbaxy) to delay the market entry of cheaper generic versions of citalopram.

The Commission stated that Lundbeck did not prevent market entry by successfully enforcing its patent rights but rather paid competitors not to compete, giving them the equivalent of what they would have earned had they entered the market. Lundbeck:

  • paid significant lump sums;
  • purchased generics producers' stock for the sole purpose of destroying it; and
  • offered the generics producers guaranteed profits in distribution arrangements.

The payments and other inducements from Lundbeck amounted to tens of millions of Euros and the agreements gave Lundbeck certainty that the generics producers would stay out of the market for a certain amount of time.

The Commission ruled that such agreements were a severe infringement of competition law and fined Lundbeck €93.8 million and the generics companies fines totalling €52.2 million.

Further, Lundbeck and the generics companies face the risk of further claims as any person or firm affected by anti-competitive behaviour may seek damages before the courts of Member States, as is the case with the French pharmaceutical company Servier.


Servier is currently the subject of a similar Commission investigation in relation to practices which potentially delayed the generic entry of the cardio-vascular medicine, perindopril.

The Commission has already issued a Statement of Objections stating that it is of the view that certain patent settlements agreements entered into by Servier are in violation EU competition law and that Servier unduly protected its market exclusivity by inducing its generic competitors to conclude patent settlements.

In addition to the Commission's investigation, Servier is also being sued by the Secretary of State for Health on the basis that such agreements are a breach of competition law and the NHS suffered loss as a result of the unavailability of the generic product. The Secretary of State for Health's claim is for £220 million.

Will Reverse Payment Settlement Agreements always violate competition law?

The Commission has clearly taken a hard line on reverse payment settlement agreements stating that these agreements constitute "severe infringements of EU competition law" and going so far as to say:

"Paying competitors to stay out of the market at the expense of European citizens has nothing to do with the legitimate protection of intellectual property: it is an illegal practice and the Commission will fight against it."

The US Supreme Court in FTC v. Actavis, Inc, however, seems to have taken a softer stance holding that whether reverse payment settlements breach antitrust rules depends upon the particular facts of a case, and rejecting the FTC's view that such agreements are presumptively illegal. In some cases a reverse payment settlement may be reasonable – for example, where the payment reflects traditional settlement considerations, such as avoiding litigation costs.

The Commission's rhetoric is at the moment pointing towards a stricter approach under which such agreements are presumed to infringe EU competition law.

Challenges to the basis of the Lundbeck decision

Despite the Commission's clearly bullish standpoint on this issue, Lundbeck is appealing on several grounds, some of which are of general application to the assessment of reverse payment settlements. Lundbeck contends as follows:

l The generic companies and Lundbeck were not potential competitors: The generic companies entering the market at risk and challenging the validity of the patents cannot be an expression of competition – otherwise, this would ignore the basic principle of EU law that patents are presumed to be valid until invalidity has been proven. In other words, the generics companies were not able to lawfully enter the market during the term of settlement agreements anyway.

  • The transfer of value under the settlement agreement is irrelevant for anticompetitive assessment: It is wrong to infer that the transfer of value means that the limitations agreed in the settlement agreement do not reflect the parties' assessment of the patent. Reverse payments aim at avoiding:

    • the inherent uncertainty of patent litigation;
    • the significant time and resource commitment required to obtain a preliminary injunction; and
    • exposure to the irreversible harm an originator may suffer if infringing entry occurs before the preliminary injunction is obtained (for example, irreversible drop in re-imbursement price), considering the asymmetry of risk between the originator and the generic company.
  • The correct test for assessing whether a patent settlement agreement is anti-competitive should be whether the restrictions in the settlement agreement go further than the scope of the patent: Settlement agreements within the scope of the patent are not anti-competitive because:

    • they have the legitimate purpose of enforcing a valid patent;
    • they do not restrict otherwise existing competition; and
    • the same result could be achieved through court proceedings.

Such a settlement agreement would not therefore restrict market entry any more than the patent does.

A decision on the Lundbeck appeal is expected within the next two to three years. In the meantime it will be interesting to see whether the Commission retains its current approach in respect of Servier, as well as Cephalon, Inc. and Johnson & Johnson which are also currently being investigated. The Commission's findings in those investigations are expected later this year.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Christopher Birch
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions